Towards validation of statistically reliable biomarkers

[1] Surrogate marker evaluation from an information theory perspective [J]. BIOMETRICS, 2007, 63 (01) : 180 - 186

[2] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95

[3] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2495 - 2499

[4] Bloom JC., 2003, BIOMARKERS CLIN DRUG

[5] Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10): : 540 - 551

[6] Burzykowski T., 2005, EVALUATION SURROGATE

[7] Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J]. LANCET, 2000, 356 (9227) : 373 - 378

[8] Criteria for the validation of surrogate endpoints in randomized experiments [J]. BIOMETRICS, 1998, 54 (03) : 1014 - 1029

[9] Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[10] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192

[1] Surrogate marker evaluation from an information theory perspective [J]. BIOMETRICS, 2007, 63 (01) : 180 - 186

[2] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95

[3] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2495 - 2499

[4] Bloom JC., 2003, BIOMARKERS CLIN DRUG

[5] Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10): : 540 - 551

[6] Burzykowski T., 2005, EVALUATION SURROGATE

[7] Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J]. LANCET, 2000, 356 (9227) : 373 - 378

[8] Criteria for the validation of surrogate endpoints in randomized experiments [J]. BIOMETRICS, 1998, 54 (03) : 1014 - 1029

[9] Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[10] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192